Sign In
Buy SLGN
Silgan Holdings Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $0.740 |
| EPS actual | $0.780 |
| EPS Surprise | 5.41% |
| Revenue estimate | 1.51B |
| Revenue actual | 1.561B |
| Revenue Surprise | 3.38% |
| Release date | Feb 04, 2026 |
| EPS estimate | $0.650 |
| EPS actual | $0.670 |
| EPS Surprise | 3.08% |
| Revenue estimate | 1.459B |
| Revenue actual | 1.469B |
| Revenue Surprise | 0.646% |
| Release date | Oct 29, 2025 |
| EPS estimate | $1.21 |
| EPS actual | $1.22 |
| EPS Surprise | 0.83% |
| Revenue estimate | 1.462B |
| Revenue actual | 2.009B |
| Revenue Surprise | 37.41% |
| Release date | Jul 30, 2025 |
| EPS estimate | $1.03 |
| EPS actual | $1.01 |
| EPS Surprise | -1.94% |
| Revenue estimate | 1.944B |
| Revenue actual | 1.539B |
| Revenue Surprise | -20.82% |
Last 4 Quarters for Silgan Holdings
Below you can see how SLGN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $47.30 |
| EPS estimate | $1.03 |
| EPS actual | $1.01 |
| EPS surprise | -1.94% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $55.37 |
| Jul 25, 2025 | $55.72 |
| Jul 28, 2025 | $55.47 |
| Jul 29, 2025 | $55.80 |
| Jul 30, 2025 | $47.30 |
| Jul 31, 2025 | $46.53 |
| Aug 01, 2025 | $45.68 |
| Aug 04, 2025 | $45.81 |
| Aug 05, 2025 | $46.45 |
| 4 days before | -14.57% |
| 4 days after | -1.80% |
| On release day | -1.63% |
| Change in period | -16.11% |
| Release date | Oct 29, 2025 |
| Price on release | $38.66 |
| EPS estimate | $1.21 |
| EPS actual | $1.22 |
| EPS surprise | 0.83% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $44.64 |
| Oct 24, 2025 | $44.58 |
| Oct 27, 2025 | $44.74 |
| Oct 28, 2025 | $44.73 |
| Oct 29, 2025 | $38.66 |
| Oct 30, 2025 | $38.26 |
| Oct 31, 2025 | $38.62 |
| Nov 03, 2025 | $38.85 |
| Nov 04, 2025 | $38.61 |
| 4 days before | -13.40% |
| 4 days after | -0.129% |
| On release day | -1.03% |
| Change in period | -13.51% |
| Release date | Feb 04, 2026 |
| Price on release | $47.97 |
| EPS estimate | $0.650 |
| EPS actual | $0.670 |
| EPS surprise | 3.08% |
| Date | Price |
|---|---|
| Jan 29, 2026 | $42.71 |
| Jan 30, 2026 | $43.15 |
| Feb 02, 2026 | $43.19 |
| Feb 03, 2026 | $43.76 |
| Feb 04, 2026 | $47.97 |
| Feb 05, 2026 | $48.87 |
| Feb 06, 2026 | $48.89 |
| Feb 09, 2026 | $48.68 |
| Feb 10, 2026 | $48.78 |
| 4 days before | 12.32% |
| 4 days after | 1.69% |
| On release day | 1.88% |
| Change in period | 14.21% |
| Release date | Apr 29, 2026 |
| Price on release | $39.55 |
| EPS estimate | $0.740 |
| EPS actual | $0.780 |
| EPS surprise | 5.41% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $39.73 |
| Apr 24, 2026 | $39.02 |
| Apr 27, 2026 | $39.08 |
| Apr 28, 2026 | $38.78 |
| Apr 29, 2026 | $39.55 |
| Apr 30, 2026 | $40.55 |
| May 01, 2026 | $39.72 |
| May 04, 2026 | $39.30 |
| May 05, 2026 | $39.45 |
| 4 days before | -0.453% |
| 4 days after | -0.253% |
| On release day | 2.53% |
| Change in period | -0.705% |
Silgan Holdings Earnings Call Transcript Summary of Q1 2026
Silgan reported a resilient start to 2026 with first-quarter results near the high end of guidance driven by operational execution, strong pet-food volumes (metal containers) and double-digit organic growth in fragrance & beauty (dispensing & specialty closures). Net sales rose 6% to $1.6 billion; adjusted EBIT was $152 million (down modestly year-over-year) and adjusted EPS was $0.78. Management raised full-year adjusted EPS guidance slightly to $3.73–$3.93, while confirming free cash flow of ~ $450 million and CapEx of ~$310 million. Key near-term headwinds include inflationary resin pressure (management expects ~ $50 million of incremental resin cost in the DSC segment to hit adjusted EBIT by ~ $10 million in Q2) and weather-related production disruption that will shift some volume timing into later quarters. The company remains focused on commercializing new wins (particularly in fragrance & beauty, health-care dispensing and pet food), active but disciplined M&A with strict return hurdles, and returning leverage to target levels via free cash flow generation.
